Related Experiment Videos
[Fabry disease: data from four families]
P H Slee1, L J van Boven, D S Slee
1St. Antonius Ziekenhuis, afd. Inwendige Ziekten, Postbus 2500, 3430 EM Nieuwegein. pslee@knmg.nl
Insights
Fabry disease, a genetic disorder, is caused by alpha-galactosidase A deficiency. Identifying specific gene mutations like Gln386Stop and Met72Arg is crucial for early diagnosis and potential therapies.
Area of Science:
- Genetics
- Biochemistry
- Medical Research
Background:
- Fabry disease is an X-linked recessive lysosomal storage disorder.
- It results from a deficiency in the enzyme alpha-galactosidase A.
- Early research described affected families, highlighting the need for genetic understanding.
Observation:
- A fourth family with Fabry disease was investigated.
- Three affected individuals in this family shared the Gln386Stop mutation in the alpha-galactosidase gene.
- Another family exhibited the Met72Arg mutation.
Findings:
- Identified specific mutations (Gln386Stop and Met72Arg) in the alpha-galactosidase gene in families with Fabry disease.
- These mutations lead to a deficiency in alpha-galactosidase A activity.
- Confirmed the genetic basis of Fabry disease in the studied families.
Implications:
- Early and accurate diagnosis of Fabry disease is critical due to diagnostic delays.
- Understanding specific mutations aids in genetic counseling and carrier identification.
- Emerging therapeutic options underscore the importance of timely diagnosis for Fabry disease patients.
Abstract:
In 1988 three families were described in this journal with Fabry's disease, an X-linked recessive lysosomal storage disorder caused by the deficiency of alpha-galactosidase A. A fourth family contained four affected men of whom one was unavailable for evaluation. The other three had the same mutation in de alpha-galactosidase gene, notably Gln386Stop, leading to the change of a glutamine codon into a stop codon. Genetic investigation in one of the other families revealed the Met72Arg mutation. The classical symptoms of the disease (angiokeratomata, acroparaesthesias, hypohidrosis and lucid areas in the cornea) are frequently only recognized after a doctor's delay that may be as long as decades. The recognition of this disease is even more important now, as therapeutic possibilities are in sight.